CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
Cell Therapeutics
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00270907
First received: December 28, 2005
Last updated: February 11, 2013
Last verified: February 2013
  Purpose

The goal of this phase I clinical study is to find the highest safe dose of gemcitabine and CT-2103 that can be given in combination for the treatment of metastatic breast cancer. The safety and effectiveness of this combination will also be studied. This clinical trial will be offered to patients who are being considered for treatment with gemcitabine. Research lab samples and research biopsies will not be requested as part of this study.


Condition Intervention Phase
Metastatic Breast Cancer
Breast Cancer
Drug: CT-2103
Drug: Gemcitabine
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Maximum Tolerated Dose (MTD) of CT-2103 [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]
    MTD defined as the level of CT-2103 at which 2 out of 6 patients had dose limiting toxicity (DLT) where the primary DLT events of CT-2103 are uncomplicated neutropenia, febrile neutropenia, and/or grade 3 neuropathy. Assessments during the first cycle of therapy, where cycle is 21 days.


Secondary Outcome Measures:
  • Number of Participants with Response [ Time Frame: 6 weeks following chemotherapy ] [ Designated as safety issue: No ]
    Evaluation of response in participants with measurable disease after each 6 weeks of chemotherapy


Enrollment: 13
Study Start Date: December 2005
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CT-2103 + Gemcitabine
CT-2103 135 mg/m^2 intravenous (IV) on Day 1. Gemcitabine 1000 mg/m^2 IV on Day 1 and 8.
Drug: CT-2103
135 mg/m^2 IV on Day 1.
Other Name: Xyotax
Drug: Gemcitabine
1000 mg/m^2 IV on Day 1 and 8.
Other Name: Gemzar

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.
  2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.
  3. Previous taxane therapy is allowed.
  4. Age >/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.
  5. Eastern Cooperative Oncology Group (ECOG) performance status </= 2 (Karnofsky >/= 60%).
  6. Measurable disease is not required.
  7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.
  8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.
  9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.
  10. Patients must have normal organ and marrow function as defined below: leukocytes >/= 3,000/ul; absolute neutrophil count >/= 1,500/ul; platelets >/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) </= 2.5 * institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance >/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).
  11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.

Exclusion Criteria:

  1. Patients with preexisting neuropathy >/= grade 2.
  2. Patients may not be receiving any other investigational agents.
  3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.
  5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.
  7. Previous history of stem cell transplantation.
  8. History of central nervous system metastases.
  9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00270907

Locations
United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Cell Therapeutics
Investigators
Principal Investigator: Marjorie Green, MD M.D. Anderson Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00270907     History of Changes
Other Study ID Numbers: 2005-0133
Study First Received: December 28, 2005
Last Updated: February 11, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Metastatic Breast Cancer
Breast Cancer
CT-2103
Gemcitabine
Xyotax
Gemzar

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Gemcitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Radiation-Sensitizing Agents

ClinicalTrials.gov processed this record on April 23, 2014